|
 |
 |
 |
 |
|
 |
|
|
|
|
 We supply clinically proven products and services
to meet a broad spectrum of healthcare needs – including the early detection of disease, prevention,
accurate diagnosis and appropriate treatment and monitoring.
Our products
and services can help to prevent and cure diseases, hasten recovery or alleviate symptoms – helping
to improve quality of life, and even to save lives. They can also provide economic benefits by reducing
treatment times, minimising hospital stays and helping people return to work faster.
Innovation
is the core of our business strategy and the secret of our success. Patients’ health is our top priority
– driving our efforts to create innovative solutions to address unmet medical needs and thus add real
value back to society.
This is evident in the number of innovative products
we have on the market. Of our top-ten- selling pharmaceuticals, eight were the first marketed products
of their kind, and some are still ungiue. Leading brands include::
| Oncology | |
| Avastin: | is a recombinant humanized anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody (IgG1). Avastin is used in combination with intravenous 5-fluorouracil–based chemotherapy for the first-line treatment of patients with metastatic carcinoma of the colon or rectum. In the US, it is also approved to treat metastatic non-squamous, non-small cell lung cancer (NSCLC).
|
| Herceptin: | is a humanized antibody designed to target and block the function of HER2 protein over expressing cells. Herceptin is used in combination therapy with paclitaxel as first-line treatment of metastatic breast cancer (MBC) and as second-/third-line monotherapy. In Europe it is approved for use in patients with early-stage HER2-positive breast cancer following surgery and standard chemotherapy.
|
| MabThera: | MabThera /Rituxan: is a therapeutic antibody which binds to the CD20 antigen on the surface of normal and malignant B-cells. MabThera is used for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL). MabThera is also indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or are intolerant to current treatment options including one or more tumour necrosis factor (TNF) inhibitors.
|
| Tarceva: | is a small molecule designed to target the human epidermal growth factor receptor 1 (HER1) pathway. Tarceva is an oral tablet taken once a day for the treatment of advanced non-small cell lung cancer (NSCLC). In the US, it is also approved to treat metastatic pancreatic cancer.
|
| Xeloda: | is an orally administered prodrug of 5'-deoxy-5-fluropuridine which is converted to 5-fluorouracil (5-FU). Xeloda is the first oral chemotherapy for the treatment of both metastatic breast and colorectal cancers, and as an adjuvant treatment in colon cancer.
|
| Virology | |
| Pegasys: | is the most frequently prescribed pegylated interferon for patients with hepatitis C. The benefits of Pegasys are derived from its unique large 40 kilodalton branched-chain PEG construction, which allows constant viral suppression over the course of a full week. Pegasys is the only pegylated interferon available as a ready-to-use solution. Pegasys also been approved in over 40 countries around the world for the treatment of chronic hepatitis B including the EU, Switzerland, Hong Kong, New Zealand, Taiwan and Thailand and is the only pegylated interferon with this indication.
|
| Tamiflu: | is an oral antiviral treatment for treatment of influenza A and B, and belongs to a class of medicines called neuraminidase inhibitors (NAI). These medicines prevent the influenza virus from spreading inside the body and are designed to be active against all clinically relevant influenza virus strains. Tamiflu can be used both for prevention and treatment of influenza.
|
| Transplantation | |
| CellCept: | an immunosuppressant medication, is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept is taken with other anti-rejection drugs.
|
| Anaemia | |
NeoRecormon/
Epogin: | a recombinant human erythropoietin (rhEPO), which is used widely and effectively in patients with renal anaemia has also been shown to be effective and well tolerated in the prevention and treatment of the anaemia associated with a range of lymphoid and solid tumours.
|
| | |
|
|
|
|
|
|
print this page